| Literature DB >> 31641019 |
Abstract
Cell structure depends on the cortex, a thin network of actin polymers and additional proteins underlying the plasma membrane. The cell polarity kinase Par-1 is required for cells to form following syncytial Drosophila embryo development. This requirement stems from Par-1 promoting cortical actin caps that grow into dome-like metaphase compartments for dividing syncytial nuclei. We find the actin caps to be a composite material of Diaphanous (Dia)-based actin bundles interspersed with independently formed, Arp2/3-based actin puncta. Par-1 and Dia colocalize along extended regions of the bundles, and both are required for the bundles and for each other's bundle-like localization, consistent with an actin-dependent self-reinforcement mechanism. Par-1 helps establish or maintain these bundles in a cortical domain with relatively low levels of the canonical formin activator Rho1-GTP. Arp2/3 is required for displacing the bundles away from each other and toward the cap circumference, suggesting interactions between these cytoskeletal components could contribute to the growth of the cap into a metaphase compartment.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31641019 PMCID: PMC6891076 DOI: 10.1083/jcb.201903152
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1.Par-1 kinase activity is required for (A) Schematic side views of three cortical nuclei. At interphase and prophase, each nucleus induces an apical actin cap (green) encircled by an actomyosin border (orange; shown in cross section). By metaphase, each cap grows into a compartment for a mitotic spindle. (B) Cycle 12 metaphase. For control RNAi embryos (shRNA targeting nonexpressed mCherry), phalloidin-stained (F-actin positive) furrows fully surround each tubulin-stained mitotic spindle. With par-1 RNAi, many furrows are lost, and abnormal interspindle contacts arise (arrowheads). Coexpression of RNAi-resistant GFP–Par-1 rescues the par-1 RNAi defects, but a kinase-deficient (KD) version does not. Both Par-1 constructs localize to the embryo cortex (bottom right panels). (C) Furrow defects quantified as three classes (see Materials and methods). Embryo numbers on the bars.
Figure 2.Par-1 localizes to actin cap bundles, actomyosin borders, and mitotic spindles. (A) Overexpressed GFP–Par-1 live with RNAi depletion of endogenous Par-1. Apical projections show caps (one bracketed). At interphase and prophase, GFP–Par-1 localizes to cap bundles (white arrows), a pattern that dissipates into metaphase and anaphase. Basal projections show GFP–Par-1 at the actomyosin border of each cap (yellow arrows), at centrosomes (purple arrows), and at portions of the anaphase central spindle (red arrowheads). Time = 0 is arbitrary. (B) Par-1–GFP expressed from an endogenous gene trap. At interphase, Par-1–GFP in cap bundles (white arrows and inset). At metaphase, Par-1–GFP enriched at actin cap accumulations, mitotic spindle centrosomes (purple arrows), and actomyosin borders (yellow arrow). Photobleaching of weakly expressed Par-1–GFP hindered full cell cycle imaging of the same embryo. (A and B) Images deconvolved. Time given in minutes and seconds.
Figure 3.Depletion of Par-1 or Dia reduces cap growth. (A) Moe-ABD–GFP decorates the caps. For control mCherry RNAi, each cap grows centrifugally in the apical plane (one cap bracketed) and then bends inward, forming compartment furrows (green arrows). With par-1 or dia RNAi, caps initiate, but centrifugal growth (one cap bracketed) and furrows (green arrows) are reduced. Time = 0 is arbitrary. Genotypes begin at the same stage. (B) Cap area versus time for control, par-1, and dia RNAi cycle 11 embryos. Caps quantified every third time frame from initial appearance to their meeting with neighboring caps (see Materials and methods). Just before the meeting of neighboring control caps (207 s), cap areas were significantly larger for controls versus par-1 or dia RNAi (P < 0.01 for each comparison). Time given in minutes and seconds.
Figure 8.Par-1 is required for both Dia and actin to form cap bundles, whereas RhoGEF2 and Rok mainly promote myosin at the borders. Dia and phalloidin staining in embryos endogenously expressing Zip-GFP. Zip-GFP recruited to actomyosin borders of control and par-1 RNAi embryos (note disorganization with par-1 RNAi). Dia and F-actin are cortical in par-1 RNAi embryos but form cap bundles of controls (arrows). Observed in 16/16 control RNAi embryos and 8/8 par-1 RNAi embryos at cycle 11. For RhoGEF2 RNAi embryos and Rok RNAi embryos, Zip-GFP was lower in borders versus control. Caps of RhoGEF2 RNAi embryos and Rok RNAi embryos displayed Dia-positive actin bundles (arrows). Note the general disorganization of the Rok RNAi caps. Observed in 16/16 RhoGEF2 RNAi embryos (combined data of two shRNA constructs) and 14/14 Rok RNAi embryos at cycle 11. Dia and phalloidin images deconvolved.
Figure 4.Par-1 and Dia promote cap actin bundles, and Arp3 promotes a separate cap actin network. (A) Tubulin staining shows cell cycle stage (note spindles). Phalloidin shows F-actin. Control mCherry RNAi caps show a combination of punctate and bundle-like F-actin (arrows) at prophase. Both pools persist to metaphase with many bundles then around the cap periphery. par-1 or dia RNAi caps display only punctate F-actin and no bundles at both stages. Arp3 RNAi caps dominated by actin bundles at both stages (arrows). Images deconvolved (squares show the detection of actin bundles and puncta in single caps without deconvolution). (B) Dia and GFP–Par-1 (expressed from a UAS construct) in Arp3 RNAi caps. Arrows indicate phalloidin-stained actin bundles. (C) Actin bundle quantifications for cycle 10 prophase of the embryo numbers and genotypes indicated. Asterisks indicate significant differences versus control RNAi.
Figure 5.(A and B) Heterozygosity for the kinase-null allele par-1w3 has no furrow effects (top). For embryos expressing a weaker dia shRNA construct, par-1w3 heterozygosity enhanced furrow defects relative to sibling embryos heterozygous for a balancer chromosome (quantified in B as in Fig. S3 A). (C) Embryos expressing the weaker dia shRNA constructs display only punctate cap F-actin with GFP coexpression, bundle-like (arrows) plus punctate cap F-actin with GFP–Par-1 coexpression, and only punctate cap F-actin with coexpression of Par-1–KD. Both Par-1 constructs localize to the cortex. The active Par-1 construct is enriched along actin bundles (arrows). Images deconvolved. (D and E) Actin organization quantified as in Fig. 4 C (embryo numbers indicated). Asterisks indicate significant differences versus GFP control.
Figure 6.Par-1 and Dia colocalize along extended regions of actin bundles, and Arp3 has a punctate cortical distribution. (A) Dia and phalloidin staining of embryos overexpressing GFP–Par-1. Before nuclear division at the embryo cortex, GFP–Par-1, Dia, and F-actin colocalize at bundles (arrows) of the broad, cap-free cortical network. At cycle 10, caps arise and GFP–Par-1, Dia, and F-actin colocalize at bundles at their apical surface (arrows) and at ingressing furrows. (B) Overexpressed Arp3-GFP puncta across the apical cap surface live. (C) Overexpressed Arp3-GFP puncta without enrichment at Dia-positive bundles (arrow) after fixation. (A–C) Images deconvolved.
Figure 9.Dia and F-actin are both required for a bundle-like distribution of Par-1. (A) Control or dia RNAi in embryos expressing endogenous Par-1–GFP and stained with phalloidin and Dia antibodies. In control caps, Par-1–GFP at Dia-positive actin bundles (arrows). In dia RNAi caps, Par-1–GFP and F-actin were cortical but bundles were not detected, and Dia was minimally detected. Observed in 12/12 control embryos and 13/13 dia RNAi embryos at cycles 10 and 11. Images deconvolved (except for Dia staining). (B) Effects of Latrunculin A or carrier injection on endogenous Par-1–GFP in live embryos. Par-1–GFP–positive bundles (white arrows) were observed in carrier control caps, but not Latrunculin A caps. Par-1–GFP–positive centrosomes were observed in both cases (yellow arrows). Observed in 7/7 controls and 6/6 Latrunculin A–injected embryos at cycles 11 and 12.
Figure 7.A Rho1-GTP sensor localizes minimally to caps and is not promoted by Par-1. (A) The Rho1-GTP sensor Anillin-RBD-GFP enriched at actomyosin borders of control embryos, and with RhoGEF2 RNAi (observed in 15/15 control RNAi embryos and 12/14 RhoGEF2 RNAi embryos [combined data of two shRNA constructs] at cycle 11). (B) Rho1-GTP sensor detected at bundle-like structures of early caps (arrows) in controls, but its levels were higher in actomyosin borders. With furrow ingression, signal reduced in caps and increased in actomyosin borders. par-1 RNAi did not diminish the Rho1-GTP sensor signal (observed in 5/5 par-1 RNAi embryos compared with the controls). With par-1 RNAi, the sensor signal seemed spatially disorganized and elevated. Time = 0 is arbitrary. Genotypes begin at the same stage. Time given in minutes and seconds.
Figure 10.Arp2/3 is required for displacing actin bundles away from each other and toward the cap circumference. (A–D) Moe-ABD–GFP in single cycle 11 caps. Time = 0 is arbitrary. Genotypes begin at the same stage. (A) In control RNAi during early cap growth, strongest bundle-like signal is observed just below apical cap surface at the base of cap folds (top row; purple asterisks at either side of a bundle in side and surface views). Bottom two rows show bundle displacements away from each other (double-headed arrows) and to cap circumference (green dots). At final time point, apical cap is flattened and largely devoid of bundles. Observed in 7/7 embryos. (B) With dia RNAi, Moe-ABD–GFP only labeled puncta across the cap. Bundles not detected. Observed in 7/10 embryos (3/10 had fragmented bundles). (C) With Arp3 RNAi, bundles detected but not associated with folds (side views) and collapsed toward the cap center over time (purple dots). 7/10 embryos lacked folds. Bundles collapsed in 5/10 embryos. No bundle movement in 3/10 embryos. Centrifugal bundle displacement in 2/10 embryos. (D) With zip RNAi, bundles associated with folds (side views) displaced from each other (double-headed arrows) and toward cap circumference (green dots). Note abnormal overall cap shape. Observed in 5/5 embryos. (E) Model of bundle induction mechanism and how bundles might function as part of a composite material for metaphase compartment formation (see Discussion). Time given in minutes and seconds.
Resources used in this study
| Reagent | Source | Number |
|---|---|---|
| Mouse anti–β-tubulin (1:100) | Developmental Studies Hybridoma Bank (DSHB) | DSHB Cat# E7, RRID:AB_528499 |
| Rabbit anti-Dia (1:3,500) | S. Wasserman, University of California at San Diego, La Jolla, CA | N/A |
| Rabbit anti-Amph (1:1,000) | G. Boulianne, Hospital for Sick Children, Toronto, Ontario, Canada | N/A |
| Mouse anti-Dlg (1:100) | DSHB | DSHB Cat# 4F3, RRID:AB_528203 |
| Alexa Fluor 568–conjugated phalloidin (1:200) | Invitrogen | Cat# A-12380 |
| Goat anti-mouse Alexa Fluor 568 (1:500) | Invitrogen | Cat# A-11004, RRID:AB_141371 |
| Goat anti-mouse Alexa Fluor 647 (1:500) | Invitrogen | Cat# A-21235, RRID:AB_141693 |
| Goat anti-rabbit Alexa Fluor 488 (1:500) | Invitrogen | Cat# A-11008, RRID:AB_143165 |
| Goat anti-rabbit Alexa Fluor 568 (1:500) | Invitrogen | Cat# A-11011, RRID:AB_143157 |
| Goat anti-rabbit Alexa Fluor 647 (1:500) | Invitrogen | Cat# A-21245, RRID:AB_141775 |
| Aqua Polymount | Polysciences | Cat #18606-5 |
| Halocarbon oil (series 700) | Halocarbon Products | Cat #9002-83-9 |
| Maternal-α4-tubulin-GAL4::VP16 | M. Peifer, University of North Carolina at Chapel Hill, Chapel Hill, NC | N/A |
| UASp-mCherry-shRNA | Bloomington Drosophila Stock Center (BDSC) | BDSC #35785 |
| UASp-Par-1-shRNA | BDSC | BDSC #35342 |
| UASp-Arp3-shRNA | BDSC | BDSC #53972 |
| UASp-Dia-shRNA (33424) | BDSC | BDSC #33424 |
| UASp-Dia-shRNA (35479) | BDSC | BDSC #35479 |
| UASp-RhoGEF2-shRNA (34643) | BDSC | BDSC #34643 |
| UASp-RhoGEF2-shRNA (76255) | BDSC | BDSC #76255 |
| UASp-Rok-shRNA | N/A | |
| UASp-Dlg-shRNA | BDSC | BDSC #35286 |
| UASp-Zip-shRNA | BDSC | BDSC #36727 |
| UASp-GFP | U. Tepass, University of Toronto | N/A |
| UASp-GFP-Par-1 | This study | N/A |
| UASp-GFP-Par-1KD | This study | N/A |
| UASp-Mbs | This study | N/A |
| UASp-MbsT506A | This study | N/A |
| UASp-Baz-GFP | N/A | |
| UASp-BazS151AS1085A-GFP | N/A | |
| UASp-Arp3-GFP | BDSC | BDSC #39722 |
| Anillin-RBD-GFP | T. Lecuit, Developmental Biology Institute of Marseille, France | N/A |
| Par-1-GFP Trap | Flytrap | CC01981 |
| Zip-GFP Trap | Flytrap | #51564 |
| UASp-mCherry-Tubulin | N. Rusan, National Heart, Lung, and Blood Institute, Bethesda, MD | N/A |
| ncd-ncd-mRFP | BDSC | BDSC #58372 |
| sqh-Moe-ABD-GFP | D. Kiehart, Duke University, Durham Hill, NC | N/A |
| D. St Johnston, Cambridge University, Cambridge, UK | N/A | |
| Primers for | Life Technologies | N/A |
| Primers for site-directed mutagenesis to generate Par-1–KD: 5'-CGCGTTCTGCGGTGCCCCGCCATAT-3' (forward) and 5'-ATATGGCGGGGCACCGCAGAACGCG-3' (reverse) | Life Technologies | N/A |
| Primers for | Life Technologies | N/A |
| Primers for site-directed mutagenesis to generate MbsT506A: 5'-CGACGGTCTGCCCAAGGTGTCACCCTG-3' (forward) and 5'-CAGGGTGACACCTTGGGCAGACCGTCG-3' (reverse) | Life Technologies | N/A |
| Drosophila Genomics Resource Center (DGRC) | RE47050 | |
| DGRC | RE63915 | |
| pENTR | Invitrogen | Cat# A-10463 |
| pPGW | DGRC | DGRC:1077 |
| Volocity 4.2.1 | Quorum Technologies Inc. | N/A |
| ImageJ | National Institutes of Health | N/A |
| Ridge Detection 1.4.0 | ImageJ plugin | N/A |
| Adobe Photoshop CS4 | Adobe | N/A |
Synthesized maternal genotypes used in this study
| Par-1 RNAi rescue experiments |
|---|
| mgv/+; UASp-mCherry(mCh)-shRNA/+ |
| mgv/+; UASp-Par-1-shRNA/+ |
| mgv/+; UASp-GFP-Par-1 (RNAi resistant)/+; UASp-Par-1-shRNA/+ |
| mgv/+; UASp-Par-1KD-GFP (RNAi resistant)/+; UASp-Par-1-shRNA/+ |
| mgv/+; Zip-GFP trap/+; UASp-mCh-shRNA/+ |
| mgv/+; Zip-GFP trap/+; UASp-Mbs/+ |
| mgv/+; Zip-GFP trap/+; UASp-MbsT506A/+ |
| mgv/+; UASp-GFP/+ |
| mgv/+; UASp-Baz-GFP/+ |
| mgv/+; UASp-BazS151AS1085A-GFP/+ |
| mgv/+; UASp-mCh-shRNA/+ |
| mgv/+; UASp-Dlg-shRNA/+ |
| mgv/+; UASp-Dlg-shRNA/UASp-mCh-shRNA |
| mgv/+; UASp-Dlg-shRNA/UASp-Par-1-shRNA |
| mgv/+; UASp-GFP-Par-1 (RNAi resistant)/+; UASp-Par-1-shRNA/+ |
| mgv/+; Par-1-GFP trap/+; UASp-mCh-shRNA |
| mgv/+; Par-1-GFP trap/+; UASp-Dia-shRNA (35479) |
| mgv/+; sqh-Moe-ABD-GFP/+; UASp-mCh-shRNA/+ |
| mgv/+; sqh-Moe-ABD-GFP/+; UASp-Par-1-shRNA/+ |
| mgv/+; sqh-Moe-ABD-GFP/UASp-Dia-shRNA (35479) |
| mgv/+; sqh-Moe-ABD-GFP/UASp-Arp3-shRNA |
| mgv/+; sqh-Moe-ABD-GFP/+; UASp-Zip-shRNA/+ |
| mgv/+; Zip-GFP trap/+; UASp-mCh-shRNA/+ |
| mgv/+; Zip-GFP trap/+; UASp-Par-1-shRNA/+ |
| mgv/+; Zip-GFP trap/UAS-Dia-shRNA (35479) |
| mgv; UASp-mCherry-Tubulin |
| mgv/+; UASp-mCherry-Tubulin/UASp-Par-1-shRNA |
| mgv/+; ncd-ncd-mRFP/UASp-Par-1-shRNA |
| mgv/+; UASp-mCh-shRNA/+ |
| mgv/+; UASp-Par-1-shRNA/+ |
| mgv/+; UASp-Dia-shRNA (35479)/+ |
| mgv/+; UASp-Arp3-shRNA/+ |
| mgv/+; UASp-GFP-Par-1/+ |
| mgv/+; UASp-Arp3-GFP/+ |
| mgv/+; UASp-GFP-Par-1/UASp-Arp3-shRNA |
| mgv/+; |
| mgv/+; |
| mgv/+; Cyo/sqh-Moe-ABD-GFP; UASp-Dia-shRNA (33424)/+ (sibling of line above) |
| mgv/+; UASp-GFP/UASp-Dia-shRNA (33424) |
| mgv/+; UASp-GFP-Par-1 (RNAi resistant)/+; UASp-Dia-shRNA (33424)/+ |
| mgv/+; UASp-Par-1KD-GFP (RNAi resistant)/+; UASp-Dia-shRNA (33424)/+ |
| mgv/+; Zip-GFP trap/+; UASp-mCh-shRNA/+ |
| mgv/+; Zip-GFP trap/+; UASp-Par-1-shRNA/+ |
| mgv/+; Zip-GFP trap/+; UASp-RhoGEF2-shRNA (34643)/+ |
| mgv/+; Zip-GFP trap/+; UASp-Rok-shRNA/+ |
| mgv/+; Anillin-RBD-GFP/UASp-mCh-shRNA |
| mgv/+; Anillin-RBD-GFP/UASp-Par-1-shRNA |
| mgv/+; Anillin-RBD-GFP/UASp-RhoGEF2-shRNA (34643) |